


Part 482 for HIV notification, or the most current FDA Guidelines on recipient notification related to donor testing for HCV. ARC guidelines will be followed for other viral tests.

- The physician must contact Risk Management to clarify legal issues related to disclosure to any individuals other than the recipient.

<p>Approved by:</p> <p style="text-align: center;">  _____ Robert L. Booth, Jr., M.D. Associate Professor Director, Clinical Pathology/Hematopathology </p> <p>Review/Revision Completed By: Michelle Bartkowiak, MT(ASCP)SBB</p>	<p>Review/Revision Date:</p> <p>6/96 1/98 3/99 1/05 12/07 6/9/2008</p> <hr/> <p>Next Review Date: 6/1/2011</p>
<p>Policies Superseded by This Policy:</p>	

It is the responsibility of the reader to verify with the responsible agent that this is the most current version of the policy.

Reference:

- AABB Standards for Blood Banks and Transfusion Services, Current edition.
- Centers for Disease Control and Prevention. Recommendations for Prevention and Control of Hepatitis C (HCV) infections and HCV-related Chronic Disease. MMWR 1998;47(No. RR-19)
- Current Good Manufacturing Practice for Blood And Blood Components. Supplemental testing, and Donors Notification of Consignees and Blood Recipients of Recipients of Donor Test Results for anti-HCV. Docket number 98D-0143 USDHSS, FDA CBER September 1998.